# Finch Therapeutics **Source:** https://geo.sig.ai/brands/finch-therapeutics **Vertical:** Biotechnology **Subcategory:** Microbiome Therapeutics **Tier:** Emerging **Website:** finchtherapeutics.com **Last Updated:** 2026-04-14 ## Summary Finch Therapeutics develops microbiome-based medicines targeting the gut-brain and gut-immune axis with programs in autism spectrum disorder and C. difficile. ## Company Overview Finch Therapeutics is a clinical-stage biotechnology company founded in 2015 that develops microbiome medicines targeting the relationship between the gut microbiome and systemic diseases. The company is focused on two primary therapeutic areas: gastrointestinal infections including C. difficile and conditions involving the gut-brain axis including autism spectrum disorder where gut microbiome alterations have been associated with symptom severity. Finch's lead microbiome program CP101 targets recurrent C. difficile infection, competing in the same emerging microbiome therapeutics space as Seres Therapeutics. The company also conducts research on the COMET platform for autism spectrum disorder, exploring whether microbiome restoration can improve behavioral symptoms through the gut-brain connection. Finch has raised over $165M and has conducted multiple clinical trials of its microbiome medicines. The company's autism program represents a particularly innovative and scientifically ambitious program given the emerging evidence that gut microbiome composition influences neurological development and behavior. Finch's work contributes to the broader scientific validation of microbiome medicine as a legitimate therapeutic class beyond C. difficile. ## Frequently Asked Questions ### What is Finch Therapeutics? Finch Therapeutics develops microbiome medicines targeting gastrointestinal infections and gut-brain axis conditions, with programs in recurrent C. difficile infection and autism spectrum disorder. ### What is the gut-brain axis? The gut-brain axis refers to bidirectional communication pathways between the gut microbiome and the central nervous system. Research suggests that gut bacteria influence brain development and behavior, and restoring microbiome health may improve neurological symptoms. ### What is Finch's autism program? Finch's COMET platform investigates whether microbiome restoration can improve behavioral symptoms in children with autism spectrum disorder by addressing gut microbiome imbalances that have been associated with autism symptom severity in clinical studies. ### What happened to Finch Therapeutics' FIN-524 program? Finch reported disappointing results from its CP101 program for C. difficile and restructured significantly in 2023, refocusing its resources on the autism microbiome program and exploring strategic alternatives for the company. ### How does Finch collect microbiome therapeutic material? Finch sources microbiome material from rigorously screened healthy donors, then processes and formulates it into standardized pharmaceutical-grade capsules with defined microbial composition for consistent dosing. ### Is Finch Therapeutics publicly traded? Yes, Finch Therapeutics trades on Nasdaq under the ticker FNCH, though the company has undergone significant restructuring and reduction in operations following pipeline setbacks. ### What is the connection between microbiome and autism in Finch's research? Clinical studies have found that children with autism often have significantly different gut microbiome compositions compared to neurotypical children. Finch's hypothesis is that restoring microbiome diversity could influence the gut-brain axis in ways that improve behavioral outcomes. ### Who funded Finch Therapeutics? Finch has been backed by venture investors including flagship programs and went public via IPO in 2021, raising capital to advance its microbiome therapeutic pipeline across multiple indications. ### What is Finch Therapeutics' lead drug candidate? Finch's lead product candidate is CP101, an oral, full-spectrum microbiome therapy targeting recurrent Clostridioides difficile infection (rCDI). CP101 is in Phase 2 clinical trials and competes with approved live biotherapeutic products like Seres Therapeutics' Vowst and Ferring's Rebyota in the emerging microbiome therapeutics market. ### What is Finch Therapeutics' COMET platform? COMET (Consortium of Microbiome Engraftment and Translation) is Finch's research platform for autism spectrum disorder (ASD). The platform investigates whether microbiome restoration can improve behavioral symptoms in ASD patients through the gut-brain axis. Finch is conducting clinical research to identify which ASD patients have gut microbiome alterations amenable to therapeutic intervention. ### How does Finch's microbiome therapy work mechanistically? Finch's CP101 delivers a comprehensive community of bacteria from healthy human donors in an oral capsule format designed to colonize the gut and restore microbial diversity. Unlike fecal microbiome transplant (FMT), CP101 is manufactured as a consistent, characterized pharmaceutical product with defined composition and rigorous safety testing. ### What is Finch Therapeutics' financial status? Finch Therapeutics is a publicly listed clinical-stage biopharmaceutical company (Nasdaq: FNCH). The company has no approved products and operates on a research funding model typical of clinical-stage biotechs. Its financial runway and pipeline progress are closely watched by investors given the competitive microbiome therapeutics landscape following competitor approvals. ### How does Finch Therapeutics compete with approved microbiome products? Finch competes with Seres Therapeutics' Vowst and Ferring's Rebyota, both of which received FDA approval for rCDI in 2023. Finch's CP101 differentiates on oral dosing convenience and full-spectrum microbiome composition. The company must demonstrate a competitive efficacy and safety profile to gain market share in an increasingly crowded rCDI treatment space. ## Tags startup, healthtech, technology, public, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*